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Background: Steroid usage has been considered as a leading cause of non-traumatic osteonecrosis of the femoral
head (ONFH), which is involved in hypo-fibrinolysis and blood supply interruption. Genetic polymorphisms in
plasminogen activator inhibitor-1 (PAI-1) have been demonstrated to be associated with ONFH risk in several
populations. However, this relationship has not been established in Chinese population. The aim of this study was
to investigate the association of PAI-1 gene polymorphisms with steroid-induced ONFH in a large cohort of Chinese
population.
Methods: A case–control study was conducted, which included 94 and 106 unrelated patients after steroid
administration recruited from 14 provinces in China, respectively. Two SNPs (rs11178 and rs2227631) within PAI-1
were genotyped using Sequenom MassARRAY system.
Results: rs2227631 SNP was significantly associated with steroid-induced ONFH group in codominant (P = 0.04) and
recessive (P = 0.02) models. However, there were no differences found in genotype frequencies of rs11178 SNP
between controls and patients with steroid-induced ONFH (all P > 0.05).
Conclusions: Our data offer the convincing evidence for the first time that rs2227631 SNP of PAI-1 may be
associated with the risk of steroid-induced ONFH, suggesting that the genetic variations of this gene may play an
important role in the disease development.
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Non-traumatic osteonecrosis of femoral head (ONFH)
represents an intractable bone disease, pathophysio-
logically characterized by progressive collapse of the
femoral head because of a disturbance in the supply of
blood and anomalies in the fibrinolytic system [1,2].
Since this ischemic necrosis of the femoral head and
deterioration of hip joint function may significantly
affect patient quality of life, it is urgent to clarify the
pathogenic mechanisms regarding this disease. Recent
studies have demonstrated that various factors, such as
steroid usage, alcoholism, infections, marrow infiltrat-
ing diseases, coagulation defects and some autoimmune
diseases may be associated with non-traumatic ONFH
[3-5]. Among them, steroid usage has been considered
as a leading cause of non-traumatic ONFH. Currently,
more than 30 million Americans require steroid drugs
as a part of their treatment regime, and up to 40% of
steroid users develop some degree of ONFH depending
on both the duration of therapy and dose [6]. There are
three pathophysiological characteristics on patients with
steroid-induced ONFH as following: (1) Steroid-induced
ONFH is an iatrogenic disease and develops at a very early
stage during steroid administration; (2) Most patients with
symptomatic steroid-induced ONFH eventually need sur-
gery (usually total hip arthroplasty) within a few years of
onset, however, these patients often require multiple in-
creasingly difficult surgeries over the course of a lifetime
because the average age at presentation is very young
(about 33 years of age); (3) Not all patients with steroid
administration develop steroid-induced ONFH, which
may be caused by the individual variation to steroids sen-
sitivity [7,8]. On the basis of above characteristics, it is of
great significance to identify novel and useful risk factors
to predict which patients receiving a specific dose of ster-
oid will develop ONFH, to indicate individual differences
in steroid sensitivity and to investigate the potential of
additional pathogenic mechanisms.
Although the pathogenic mechanisms of steroid-
induced ONFH have not been fully elucidated, recent
studies have demonstrated that the development of this
disease may be associated with blood coagulation in the
femoral head, which is mainly caused by the damage of
the endotheliocyte membrane, as well as the tendency
for blood to congeal [9,10]. Plasminogen activator in-
hibitor (PAI)-1 is one of the most important regulators
for the balance of the coagulation and fibrinolytic
systems [11]. It is the primary inhibitor of both tissue-
and urinary-type plasminogen activators. Changes in
PAI-1 may lead to a destabilization of the fibrinolytic
system directly, destroying the balance between blood
coagulation and fibrinolysis [12]. The product of coagu-
lation accumulates in vessels easily, and thus, the blood
stream will be limited or disrupted completely [13].Accumulating evidences have suggested the relationship
between abnormalities of PAI-1 and ONFH develop-
ment. Tan et al. [14] showed that the expression level of
PAI-1 protein was significantly upregulated in the sera
of patients with idiopathic ONFH detected by enzyme-
linked immunosorbent assay (ELISA); Hozumi et al.
[15] reported that PAI-1 expression at both mRNA and
protein levels was significantly increased by steroid
adiministration and bone marrow adipocytes may play
important roles in the development of steroid-induced
ONFH by enhancing PAI-1 expression. They also found
that simvastatin may exhibit preventive effects against
steroid-induced ONFH by suppressing PAI-1 secretion
[16]. PAI-1 antigen levels are determined by genetic
polymorphisms within the PAI-1 gene. It has been indi-
cated that the plasma PAI-1 antigen level may be higher
in the 4G/4G genotype than in the 5G/5G genotype
[17]; Glueck et al. [18] first reported that the genotype
frequency of 4G/4G was 41% in ONFH patients and
20% in healthy control subjects from USA; Ferrari et al.
[19] investigated the relationship between the incidence
of postrenal transplant ONFH and PAI-1 4G/5G poly-
morphism in Swiss population and reported that devel-
opment of ONFH may be more frequently observed in
the 4G/4G genotype; Kim et al. [20] also found that the
4G allele of rs1799889, A allele of rs2227631, and C
allele of rs11178 were significantly associated with
increased ONFH risk in Korea population. In contrast,
Asano et al. [21] using Japanese population suggested
that plasma PAI-1 levels were highest in ONFH patients
with the 4G/4G genotype, but that the incidence of
ONFH was not related to this genotype. These findings
indicated that the genetic polymorphisms within the
PAI-1 gene may play an important role in the develop-
ment of ONFH.
Since the relationship between the genetic polymor-
phisms of the PAI-1 gene and the risk of steroid-induced
ONFH has not been determined in Chinese population,
we performed the current study to better understand the
association of PAI-1 gene polymorphisms with steroid-
induced ONFH in a large cohort of Chinese population.
Materials and methods
Study subjects
The study was approved by the Research Ethics Com-
mittee of Institute of Chinese Materia Medica, Wangjing
Hospital, & Institute of Hematology & Blood Diseases
Hospital, China Academy of Chinese Medical Sciences,
China. Informed consent was obtained from all of the
patients.
A total of 94 patients with steroid-induced ONFH (case
group, 40 men, 54 women; mean age: 40.22 ± 14.78 years)
and 106 patients who did not develop steroid-induced
ONFH (reference group, 64 men, 42 women; mean age:









Male 40 64 0.02
Female 54 42
Age (year)
Median (Range) 38.00 (18–82) 44.50 (18–80) 0.23
Mean 40.22 ± 14.78 43.09 ± 18.36
Body mass index
(BMI, Kg/m2)
Median (Range) 22.8 (16.9-30.8) 24.45 (18.48-30.12) <0.001
Mean 23.01 ± 3.00 24.36 ± 2.42
Concurrent or past
medical history
Hematologic diseases 23 106 <0.001
Dermatogic diseases 9 0
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consecutively enrolled at Wangjing Hospital and Institute
of Hematology & Blood Diseases Hospital of China
Academy of Chinese Medical Sciences from March 2011 to
December 2012. All the subjects are from 14 provinces in
China, including Hebei (n = 41), Beijing (n = 32), Tianjin
(n = 27), Shandong (n = 21), Henan (n = 18), Liaoning
(n = 14), Jilin (n = 11), Shanxi (n = 10), Heilongjiang (n = 10),
Neimenggu (n = 8), Guizhou (n = 3), Ningxia (n = 2), Shanxi
(n = 2) and Qinghai (n = 1). Steroid-induced ONFH was
defined by a history of a mean daily dose of ≥16.6 mg or
highest daily dose of 80 mg of predinosolone equivalent
within 1 year prior to the development of symptoms or
radiological diagnosis in asymptomatic cases [22-24].
Underlying diseases in steroid-induced ONFH were
hematologic diseases (n = 23 patients), dermatogic diseases
(n = 9 patients), renal diseases (n = 9 patients), ophthalmo-
pathy (n = 6 patients), diseases of respiratory system (n = 5
patients), and others (n = 42 patients). Patients with a
demonstrable history of direct trauma or with possible
combined causes were excluded. The clinical characteris-
tics of patients in case and reference groups were summa-
rized in Table 1.Others 42 0
Affected
Unilateral 15 - -
Bilateral 79 -
Steroid treatment
Mouth medication 74 89 0.06
Intravenous injection 36 71
Steroid dose
Large (>400 mg/d) 34 60 0.12
Middle (>100 mg/d





Median (Range) 360 (7–9490) 810 (4–79934) 0.10
Mean 1140.34 ± 2014.037 2631.54 ± 8610.278
Note: “Bolded values” refer to the statistically significant data.Candidate PAI-1 single nucleotide polymorphism (SNP)
selection
Two well-studied functional SNPs in the PAI-1 gene,
rs2227631 (−844 G/A, in the promoter) and rs11178
(+10700 C/T, in the 3′UTR), were selected in the list of
genotyping in this study for their important functions in
regulating PAI-1 expression and in the development of
ONFH. As the results of our literature retrieval from
PubMed database (http://www.ncbi.nlm.nih.gov/sites/
entrez?db=PubMed), Kim et al. [20] showed for the first
time that rs2227631 and rs11178 are essential SNPs in-
volved in the regulation of PAI-1 gene expression in
ONFH using a Korean population. According to the sub-
group analysis, they confirmed the risk effects of
rs2227631 and rs11178 in the idiopathic ONFH and men
subgroups, and those of rs11178 in the alcohol-induced
ONFH subgroup. However, no association was seen in the
steroid-induced ONFH group because of the small sample
size. In the current study, the relationships between
rs2227631 and rs11178 SNPs, and the development of
steroid-induced ONFH were investigated using a large co-
hort of Chinese population.DNA isolation
Genomic DNA was extracted from 2 mL whole-blood
samples using the QIAamp DNA Blood Mini kit (Qiagen,
Inc., Valencia, CA) following the manufacturer’s protocol.
After dilution to 20 ng/μL, DNA was distributed in 96-
well plates and stored at −80°C.PAI-1 SNP genotyping
SNP genotyping was performed on the SEQUENOM
MassARRAY® Analyzer 4 (Sequenom, Inc., San Diego,
CA, USA) using genomic DNA in a single multiplex re-
action. Primers for polymerase chain reaction (PCR)
amplification and single base extension were designed by
Sequenom Assay Design 3.1 software (Sequenom, San
Diego, CA, USA) according to the manufacturer’s in-
structions (Table 2). For quality control, genotyping was
performed without knowledge of the case/control status
of the subjects, and a random sample of 5% of cases and
Table 2 Polymerase chain reaction primers of selected SNPs
Single nucleotide polymorphism PCR primer Sequence Extension primer Sequence
rs11178 1st-primer ACGTTGGATGATAGTTTCTACCAGGCACAC 1st-primer AGGCCCTTTGCAGGAC
2nd-primer ACGTTGGATGAGACCTGGTTCCCACTGAG 2nd-primer AGGCCCTTTGCAGGAT
rs2227631 1st-primer ACGTTGGATGAAGGAAACAGGAGACCAACG 1st-primer gcaTAGCGGGCAGCTCGAA
2nd-primer ACGTTGGATGAGGATAAAGGACAAGCTGCC 2nd-primer gcaTAGCGGGCAGCTCGAG
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The reproducibility was 100%. The genotyping success
rate was over 95% (Figure 1).Statistical analysis
The software of SPSS version12.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC)
was used for statistical analysis. Continuous variables
were expressed as X  s . Statistical analysis were
performed with Fisher's exact test for any 2 × 2 tables,
Pearson χ2 test for non- 2 × 2 tables, chi-square trend
test for ordinal datum. A significant departure of
genotype frequency from Hardy-Weinberg equilibrium
(HWE) for each SNP was estimated using SNPStats
(http://bioinfo.iconcologia.net/snpstats/start.htm). Sig-
nificant differences in genotype and allele frequency
between steroid-induced ONFH cases and controls
were assessed using the χ2 test for categorical vari-
ables. An association analysis based on unconditional
binary logistic regression was carried out to determine
the odds ratio (OR) and 95% confidence interval (95%
CI) for each SNP, using age, gender, body mass indexFigure 1 Clustering graphs of genotypes for rs11178 (+10700 C/T in t
genotyping success rate was over 95%.(BMI), concurrent or past medical history, steroid dose
and days of steroid treatment as covariates. The level
of significance was set at P < 0.05.
Results
Participant demographics
Table 1 shows the general characteristics of the study
population which consisted of 94 steroid-induced
ONFH patients (case group) and 106 patients who re-
ceived steroid administration but did not develop
steroid-induced ONFH (reference group). The subjects
in the reference group were well matched with those
in the case group for age, steroid treatment, steroid
dose, and days of steroid treatment (all P > 0.05,
Table 1). However, there were significant differences in
the gender (P = 0.02), BMI (P < 0.001), and past med-
ical history (P < 0.001) distributions between the two
groups. The steroid-induced ONFH patients were
more likely in men subgroup, and to have a smaller
BMI when compared to the controls. In order to avoid
the influence of these mismatch factors on our statis-
tical results, we used them as covariates in logistic
regression analysis.he 3′UTR, A) and rs2227631 (−844 G/A in the promoter, B). The
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The frequencies of rs11178 and rs2227631 SNPs were
tested in Hardy-Weinberg formula by SNPStats (http://
bioinfo.iconcologia.net/snpstats/start.htm). The results showed
that all genotype distributions of the case and reference
groups were coherent with the assumption of Hardy-
Weinberg equilibrium [(HWE), rs11178 (P = 0.47) and
rs2227631 (P = 0.28)] (P > 0.05).
We further found significant associations of genotypic
and allelic frequencies for rs11178 and rs2227631 SNPs
of PAI-1 gene with steroid-induced ONFH. As shown in
Table 3, rs2227631 SNP was significantly associated with
steroid-induced ONFH group in codominant (P = 0.04)
and recessive (P = 0.03) models. However, there were no
differences found in genotype frequencies of rs11178
SNP between controls and patients with steroid-induced
ONFH (all P > 0.05, Table 3).
Discussion
Steroid exhibits diverse activities in multiple organs and
hypercortisolism may cause various disorders including
ONFH which is a common complication induced by high-
dose administration of steroid [25]. The disease pathogen-
esis seems to be multifactorial and is still unclear. Recent
studies have demonstrated that both hypo-fibrinolysis and
corresponding blood supply interruption are major fea-
tures in the development of steroid-induced ONFH [26].
The genetic variations of genes which are implicated in
these pathophysiological processes have been hypothe-
sized to be associated with steroid-induced ONFH. In the
present study, we determined the contributions of PAI-1
gene SNPs to steroid-induced ONFH. We demonstrated
for the first time that there may be a significant association
between rs2227631 SNP (−844 G/A) of the PAI-1 gene
and steroid-induced ONFH in Chinese population and the
A allele considerably increased disease risk.Table 3 Association between rs11178 and rs2227631 SNPs an
SNP ID Genotype Cases Control Codominant
OR (95% CI) P
rs11178 C/C 21 24 1.00
0.15
T/C 52 52 0.50
(0.20-1.23)
T/T 20 27 0.38
(0.13-1.07)
rs2227631 G/G 34 33 1.00
0.04
A/G 43 53 0.74
(0.34-1.63)
A/A 9 14 0.20
(0.05-0.73)
Note: "Bolded values" refer to the statistically significant data.It is well known that the damage of the endotheliocyte
membrane leading to the tendency for blood to congeal
is the key cause of blood coagulation [27]. PAIs may play
important roles in this process. There are two forms of
PAIs, PAI-1 and PAI-2. PAI-1 is a serine protease inhibi-
tor which is synthesized and released by endothelial cells
in blood vessel walls and PAI-2 is a thromboblastic
product [28]. PAI-1 exerts its regulatory activity on fi-
brinolysis by forming complexes with tissue plasminogen
activator (t-PA) which may activate plasminogen. Changes
in t-PA and PAI-1 lead to a destabilization of the fibrino-
lytic system directly, destroying the balance between blood
coagulation and fibrinolysis [29]. Since blood coagulation
in the femoral head is thought to be associated with
ONFH, there have been several reports regarding
increased PAI-1 secretion in blood sera of patients
with ONFH. The human PAI-1 gene, also known as the
SERPINE1 gene, is mapped on chromosome 7q21.3-q22,
and several polymorphisms within this gene have been
described [30]. Among them, 4G/5G SNP may contribute
to the strongest SNP association with plasma PAI-1 con-
centration. High PAI-1 expression levels, induced by −675
4G/5G SNP in the PAI-1 promoter, lead to suppression of
fibrinolysis through inhibition of plasminogen activator
and promotion of thrombosis [17]. The resulting increase
in intraosseous venous pressure which restricts flow to the
femoral head may culminate in osteonecrosis [18]. Previ-
ous study has reported that the frequency of the 4G/4G
genotype was greater in the patients with ONFH after
renal transplantation than in the patients without ONFH,
suggesting the association between 4G/5G SNP and the
development of ONFH in Swiss population [19]. On the
contrary, in Japanese population, it has not been dem-
onstrated a statistically significant relationship between
the 4G/5G polymorphism and the incidence of ONFH,
although the increase in the ONFH development was
observed in patients with the PAI-1 4G/4G genotyped the risk of steroid-induced ONFH
Dominant Recessive Overdominant
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disequilibrium with the widely reported 4G/5G poly-
morphism in the promoter of the PAI-1 gene, and is po-
tentially implicated in PAI-1 gene regulation [31]. Su
et al. [32] indicated that rs2227631 polymorphism was
significantly associated with coronary heart disease
(CHD) in nonsmokers; in Korean population, this SNP
was demonstrated to be a risk factor for ONFH [20],
which was in line with the results of our study that con-
firmed a significant association between rs2227631
polymorphism and the development of steroid-induced
ONFH in Chinese population. In addition to rs2227631,
rs11178 also significantly associates with increased
CHD risk in nonsmokers [32], which might be attribut-
able to strong linkage linkage disequilibrium of this
SNP with rs2227631 and rs1799889. For ONFH, recent
study of Korean population also identified an associ-
ation between rs11178 and disease risk [30]. However,
our study did not found this relationship in Chinese
population. The discrepancy between our results of
Chinese population and those of Korean population
might be ascribed to the difference in genetic back-
ground according to race, which could affect the path-
ology of steroid-induced ONFH.
There are several advantages in this study as following:
(1) we enrolled 94 patients with steroid-induced ONFH
in the case group. To the best of our knowledge, the
sample size is the largest in genetic polymorphism stud-
ies concerning steroid-induced ONFH conducted so far.
(2) We compared the polymorphisms between patients
having and not having steroid-induced ONFH. These pa-
tients had the similar background of steroid treatment,
steroid dose, and Days of steroid treatment (without sig-
nificant differences between case and reference groups),
which could not affect the distributions of genetic
polymorphisms.
Despite these advantages, there are also several limita-
tions in this study as following: (1) the heterogeneity
among patients is a real issue in clinical practice when
we are confront with steroid-induced ONFH; (2) the
precise mechanisms by which the PAI-1 polymorphisms
affect the susceptibility to steroid-induced ONFH are
still unclear. Further studies are necessary to fully ad-
dress this problem.
In conclusion, our data offer the convinced evidence for
the first time that rs2227631 SNP of PAI-1 may be associ-
ated with the risk of steroid-induced ONFH, suggesting
that the genetic variations of this gene may play an im-
portant role in the disease development. Taken together, it
is helpful to analyze rs2227631 SNP of PAI-1 for identify-
ing susceptibility to steroid-induced ONFH.Competing interests
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